Semel Institute for Neuroscience and Human Behavior

THE RARE IMPACT FUND ANNOUNCES ADDITIONAL FUNDING FOR YOUTH MENTAL HEALTH ORGANIZATIONS

Retrieved on: 
Wednesday, February 15, 2023
Organization, Trans Lifeline, Beauty, Lead, Rare Beauty, Social impact, Microgrant, San Francisco Bay Area, Peer Health Exchange, The, LOS, Yale Center for Emotional Intelligence, Mental, Research, The Jed Foundation, School, Behavior, Student, Mindfulness, VP/MS, Education, Semel Institute for Neuroscience and Human Behavior, Friends, Emotional Intelligence, UCLA, McLean Hospital, Mental health, Pharmaceutical industry, Nursing, Tutoring, Black, Service, Neuroscience

LOS ANGELES, Feb. 15, 2023 /PRNewswire/ -- The Rare Impact Fund, launched by Selena Gomez, and part of Rare Beauty's signature social impact programs, today announces an additional $1.5 million in grant support to 12 organizations expanding access to mental health services and education for young people around the world. The Rare Impact Fund was created in 2020, with the goal of raising $100 million to address youth mental health. Rare Beauty donates one percent of sales directly to the Rare Impact Fund and raises additional funds with Foundations, Corporate Partners, and individuals.

Key Points: 
  • The Rare Impact Fund was created in 2020, with the goal of raising $100 million to address youth mental health.
  • The Rare Impact Fund announces an additional $1.5 million in grant support to 12 organizations expanding access to mental health services and education for young people around the world.
  • "I am so proud to continue our commitment to addressing youth mental health with additional support for these incredible organizations," said Selena Gomez, Founder and Creator of Rare Beauty and the Rare Impact Fund.
  • In 2022, the Rare Impact Fund expanded globally, extending its reach to support a total of 23 mental health organizations.

EQS-News: Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Retrieved on: 
Sunday, January 22, 2023
Neuroscience, Peripheral nervous system, CET, Clozapine, Newron Cup, Semel Institute for Neuroscience and Human Behavior, Education, Evenamide, Clinical Global Impression, CNS, Patient, Safety, XETRA, UCLA, Congress, PANSS, TRS, Positive, European, Pharmaceutical industry, Psychiatry

85 of the 100 patients completed the 30-week treatment period with evenamide.

Key Points: 
  • 85 of the 100 patients completed the 30-week treatment period with evenamide.
  • The proportion of patients demonstrating a clinically meaningful PANSS improvement (“responders”) at week 30 more than doubled from 16.5% at week six.
  • The addition of evenamide to the current antipsychotic medication of the patients continued to be well tolerated after six months of treatment.
  • Evenamide was well tolerated with few adverse effects and 85 of 100 patients remained on treatment at 30 weeks.

Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

Retrieved on: 
Tuesday, January 3, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Neuroscience, Peripheral nervous system, CET, Clozapine, Semel Institute for Neuroscience and Human Behavior, Education, Evenamide, Clinical Global Impression, CNS, Medication, Patient, Safety, XETRA, UCLA, Congress, PANSS, TRS, Positive, European, Pharmaceutical industry, Newron Cup, Psychiatry

85 of the 100 patients completed the 30-week treatment period with evenamide.

Key Points: 
  • 85 of the 100 patients completed the 30-week treatment period with evenamide.
  • The proportion of patients demonstrating a clinically meaningful PANSS improvement (“responders”) at week 30 more than doubled from 16.5% at week six.
  • The addition of evenamide to the current antipsychotic medication of the patients continued to be well tolerated after six months of treatment.
  • Evenamide was well tolerated with few adverse effects and 85 of 100 patients remained on treatment at 30 weeks.

NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD

Retrieved on: 
Tuesday, June 14, 2022
Principal investigator, McGough, UCLA, NIH grant, Behavioural sciences, Associate, Depression, ADHD, University of California, San Francisco, Monarch, Treatment, Psychiatry, Semel Institute for Neuroscience and Human Behavior, Mental, NIH, Attention deficit hyperactivity disorder predominantly inattentive, EEG, University, National Institutes of Health, FDA, GLOBE, Patient, National, Telephony, Anticonvulsant, University of Washington School of Medicine, Population, Hospital, Safety, Pharmaceutical industry, Neuroscience

LOS ANGELES, June 14, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the University of California, Los Angeles (UCLA) led by Professor Sandra Loo received a National Institutes of Health (NIH) grant to conduct a double-blind randomized controlled trial of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD). The trial will enroll up to 225 children with moderate to severe ADHD at UCLA and Seattle Children’s Hospital for a blinded period of 4 weeks followed by an open label follow-up period of up to 1 year. Professor James McGough will be the Co-Lead at UCLA and Professor Mark Stein will lead the team at Seattle Children’s Hospital.

Key Points: 
  • Professor James McGough will be the Co-Lead at UCLA and Professor Mark Stein will lead the team at Seattle Childrens Hospital.
  • Funding for the 4-week blinded period is provided by NIH Grant 1R01MH126041-01A1 with devices and funding for the long-term open label period provided by NeuroSigma.
  • The company is developing therapies to treat a wide spectrum of neurological and neuropsychiatric disorders, including ADHD, drug-resistant epilepsy, and depression.
  • The company is currently commercializing the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA.

Connie, Steve Ballmer Commit Over $425 Million to University of Oregon to Tackle Children's Behavioral and Mental Health Crisis

Retrieved on: 
Tuesday, March 1, 2022
University, National Institute of Molecular Biology and Biotechnology, Workforce, Connie, GLOBE, Health, Mental health, National Center on Education and the Economy, Partnership, Board, Twitter, University of Oregon, Los Angeles Clippers, USAFacts, Steve Ballmer, Security agency, Association of American Universities, Education, Achievement Medal, UO, K-12, Trustee, School, Public policy, Semel Institute for Neuroscience and Human Behavior, Organization, Center, Social, Housing, Translational neuroscience, Foundation (nonprofit), Ballmer, Legislature, Institute, Molecular biology, Particle physics, Board of directors, Learning, Portland Public Schools, Student, Knowledge, Phil, Concordia University, Faculty, Association, CEO, Research, Carnegie Foundation, National, Microsoft, Medicine, Toy, Health insurance

The Portland-based institute is made possible by a lead gift of more than $425 million from Connie and Steve Ballmer, co-founders of Ballmer Group Philanthropy .

Key Points: 
  • The Portland-based institute is made possible by a lead gift of more than $425 million from Connie and Steve Ballmer, co-founders of Ballmer Group Philanthropy .
  • "Connie and Steve Ballmer, who have already provided exceptional support and inspiration for children's behavioral health, are now empowering the university to make immediate and lasting positive impacts on children's behavioral and mental health," said Michael H. Schill, University of Oregon president and professor of law.
  • "A bold effort is needed to address the behavioral and mental health needs of our youth.
  • "Oregon must take action to address the behavioral and mental health crisis that we are facing in communities across the entire state," Brown said.

Gaia Announces Ambassador Program Partnership with Demi Lovato

Retrieved on: 
Tuesday, November 2, 2021
People, Love, Teen Choice Awards, CSETI, People's Choice Awards, MTV Video Music Awards, Catalog, Apple TV, Deep Space, Xfinity, GRAMMY, Behavior, Roku, UCLA, Partnership, Demi Lovato, NASDAQ, Web Cartoonists' Choice Awards, Amazon Prime Video, Civilization, GLAAD Vanguard Award, Courage, GAIA, Center, Time, Life, Senior, Social media, Semel Institute for Neuroscience and Human Behavior, Mental health, Demi, Extraterrestrial intelligence, Music, Multimedia, American Music Awards, IOS, ALMA Award, Billboard Music Awards, Lovato, Grammy Awards, Android, Brit Awards, 31st Young Artist Awards, Consciousness, Meditation, LGBT, Video game

Globally recognized, Lovato brings one of the world's largest social media followings to Gaia's burgeoning network of conscious brand ambassadors.

Key Points: 
  • Globally recognized, Lovato brings one of the world's largest social media followings to Gaia's burgeoning network of conscious brand ambassadors.
  • Continuing down their rabbit hole, Lovato quickly fell in love with Gaia original series "Ancient Civilizations" and "Deep Space."
  • Demi Lovato is a GRAMMY-nominated singer, actor, producer, podcast host, New York Times best-selling author and activist.
  • Lovato is the host of their own podcast, 4D With Demi Lovato, where they announced that they identify as non-binary and have officially changed their pronouns to they/them.

Thomas Lehner, PhD, MPH, Joins the New York Genome Center as Scientific Director of Neuropsychiatric Disease Genomics

Retrieved on: 
Thursday, October 24, 2019
Neurology, Neuropsychiatry, Treatment of bipolar disorder, New York Genome Center, Branches of biology, Biology, Medical specialties, Joseph Buxbaum, Semel Institute for Neuroscience and Human Behavior

NEW YORK, Oct. 24, 2019 /PRNewswire/ --The New York Genome Center (NYGC) is pleased to announce the appointment of Thomas Lehner, PhD, MPH, as its Scientific Director of Neuropsychiatric Disease Genomics.

Key Points: 
  • NEW YORK, Oct. 24, 2019 /PRNewswire/ --The New York Genome Center (NYGC) is pleased to announce the appointment of Thomas Lehner, PhD, MPH, as its Scientific Director of Neuropsychiatric Disease Genomics.
  • A highly regarded expert in neuropsychiatric genomics, Dr. Lehner will join the NYGC on January 6, 2020.
  • In this new position, he will provide leadership for the NYGC's research activities in this key area, developing and spearheading the overarching scientific strategy for neuropsychiatric disease genomics research at the Center.
  • Dr. Lehner will lead the NYGC's expansion of its innovative, large-scale whole genome autism research into other neuropsychiatric disease areas including schizophrenia and bipolar disorder.